Skip to main content
Fig. 6 | BMC Medicine

Fig. 6

From: Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer

Fig. 6

Combining HRD and immune activation enhances the efficacy of identifying ACT responders. A, B OS (A) and FFI (B) by the status of combined HRD and immune activation. Log-rank test. C Multivariate Cox analysis after correcting for clinical factors such as age, AJCC stage and TNM stage. The pathology M stage is not included in the model due to incomplete information. ***P < 0.001, **P < 0.01, *P < 0.05. D The estimated likelihood ratio (LR) statistic of a Cox model in clinical factors, such as age, stage, and age and stage was compared. The change of LR statistic as features were added to the model was assessed for significance. E The area under the curve (AUC) of the combined status (orange colour), HRD status alone (green colour) and only clinical factors (grey colour) in the patient’s 5-year survival time (FFI) were compared

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us